Vol 9, No 5 (2020)
Other materials agreed with the Editors
Published online: 2020-09-28

open access

Page views 936
Article views/downloads 672
Get Citation

Connect on Social Media

Connect on Social Media

The prevalence of type 2 diabetes in patients with COVID-19: a systematic review and meta-analysis

Monireh Faghir-Gangi, Hossein Moameri, Narges Abdolmohamadi, Shahrzad Nematollahi1
Clin Diabetol 2020;9(5):271-278.

Abstract

Background. A strong link between morbidity andmortality from COVID-19 and diabetes mellitus is reported by many studies. The present study estimated the pooled prevalence of diabetes in patients with COVID-19. Methods. International scientific databases were searched until 15 April 2020. There was no limitation in time and language of the published papers. Quality assessment of studies was performed using the Newcastle-Ottawa Scale (NOS) checklist. The random effects model was used to report the pooled prevalence with 95% confidence interval (CI). Results. The pooled prevalence of diabetes in patients with COVID-19 was 14% (95% CI: 11.17). Due to high heterogeneity (I2 of 93.4%, P < 0.001), three subgroups were analyzed based on study location, age and sex. The prevalence of diabetes (P) was higher among male patients (P = 16%, 95% CI: 0.12, 0.20), patients aged ≥ 65 years (P = 19%, 95% CI: 0.08, 0.31). The prevalence of diabetes was 15% (95% CI: 0.10, 0.20) among patients in Wuhan, China and 10% in patients in other cities in China (95% CI: 0.06, 0.15), and 39% in patients from other countries (95% CI: 0.04, 0.74). Conclusion. According to the results of this systematic review, the prevalence of diabetes in patients with COVID-19 is higher in other countries compared to China. The prevalence of diabetes among COVID-19 patients was also significantly higher in men and elderlies. This evidence may be useful for health policymakers to design suitable preventive and therapeutic interventions in patients with diabetes and COVID-19.

Article available in PDF format

View PDF Download PDF file

References

  1. Kaiser UB, Mirmira RG, Stewart PM. Our Response to COVID-19 as Endocrinologists and Diabetologists. J Clin Endocrinol Metab. 2020; 105(5).
  2. World Health Organization.Coronavirus disease 2019 (COVID-19)Situation Report -72:Data as reported by national authorities by 10:00CET1 April2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2 (2.03.2020).
  3. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4): e21.
  5. Hu Y, Sun J, Dai Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020; 127: 104371.
  6. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020.
  7. Li Bo, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109(5): 531–538.
  8. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020; 288(1): 128–138.
  9. Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12(7): 6049–6057.
  10. Villabona CV. Commentary: COVID-19 and diabetes. Diabetes Res Clin Pract. 2020; 162: 108138.
  11. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol. 2020; 30(3): e2103.
  12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9): 603–605.
  13. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557–560.
  14. Higgins J, Altman D, Sterne J. assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0 (updated March 2011). The Cochrane Collaboration; 2011. The Cochrane Collaboration www handbook cochrane org (accessed 17 May 2018). 2011.
  15. Wang X, Fang J, Zhu Y, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect. 2020; 26(8): 1063–1068.
  16. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. 2020; 382(21): 2012–2022.
  17. Stoian AP, Banerjee Y, Rizvi AA, et al. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. Metab Syndr Relat Disord. 2020; 18(4): 173–175.
  18. Huang X, Wei F, Hu L, et al. Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med. 2020; 23(4): 268–271.
  19. Stein RA. COVID-19: Risk groups, mechanistic insights and challenges. Int J Clin Pract. 2020 [Epub ahead of print]: e13512.
  20. Lovato A, de Filippis C. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. Ear Nose Throat J. 2020 [Epub ahead of print]: 145561320920762.
  21. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7): 934–943.
  22. Yang Y, Liu X, Liu Y, et al. The effect of diabetes on mortality of COVID-19: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(27): e20913.